In summary, our findings showed that these plasma candidate markers, including PRDX6, FN1, and SERPINB9, may participate in PCOS development or drug management in response to reactive oxygen species, cellular oxidant detoxification, platelet degranulation, and immune response processes. This evidence concerns the gene PRDX6 and polycystic ovary syndrome.